within Pharmacolibrary.Drugs.ATC.L;

model L04AC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0036166666666666665,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.00634,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Daclizumab is a humanized monoclonal antibody that binds to the alpha subunit (CD25) of the interleukin-2 receptor, primarily used as an immunosuppressive agent. It was previously approved for the treatment of relapsing forms of multiple sclerosis and for prevention of organ transplant rejection but was withdrawn from the market due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics reported in adult patients with relapsing multiple sclerosis; parameters from IV and SC administration studies.</p><h4>References</h4><ol><li>Lei Diao, Yaming Hang, Ahmed A Othman, Ivan Nestorov, Jonathan Q Tran,Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.,Clinical pharmacokinetics,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26873229/'>https://pubmed.ncbi.nlm.nih.gov/26873229/</a></li><li>Marcus Mottershead, James Neuberger,Daclizumab.,Expert opinion on biological therapy,2007<a href='https://pubmed.ncbi.nlm.nih.gov/17916050/'>https://pubmed.ncbi.nlm.nih.gov/17916050/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC01;
